Correlation of topoisomerase Ⅱα with prognosis and anthracycline efficacy in breast cancer

doi:10.3877/cma.j.issn.1674-0807.2020.04.001

Abstract

Abstract:

Topoisomerase Ⅱα(TOP2A)is considered as a key nuclease in DNA replication and transcription. It is a proliferation marker of tumor cells and an important target of anthracyclines, which plays an important role in biological process. Many studies have shown that TOP2A gene amplification is related closely to the efficacy of anthracyclines. However, the effect of TOP2A protein expression on the prediction of anthracycline efficacy and the prognosis of breast cancer patients remains controversial. Our study reviewed the predictive and prognostic value of TOP2A protein.

Key words: Breast neoplasms, DNA topoisomerases, type Ⅱ, Anthracyclines, Prognosis

Yun Wu, Binghe Xu, Jiayu Wang. Correlation of topoisomerase Ⅱα with prognosis and anthracycline efficacy in breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2020, 14(04): 195-199.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2020.04.001

https://zhrxbzz.cma-cmc.com.cn/EN/Y2020/V14/I04/195

References 41

[1]	Nakopoulou L, Lazaris AC, Kavantzas N，et al. DNA topoisomerase Ⅱ-α immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer [J]. Pathobiology, 2000, 68(3): 137-143.
[2]	Martin M, Romero A, Cheang MC，et al. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer [J]. Breast Cancer Res Treat, 2011, 128(1): 127-136.
[3]	Shigematsu H, Ozaki S, Yasui D，et al. Overexpression of topoisomerase Ⅱα protein is a factor for poor prognosis in patients with luminal B breast cancer [J]. Oncotarget, 2018, 9(42): 26 701-26 710.
[4]	Harris LN, Broadwater G, Abu-Khalaf M，et al. Topoisomerase Ⅱα amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013 [J]. J Clin Oncol, 2009, 27(21): 3430-3436.
[5]	Jarvinen TA, Tanner M, Barlund M，et al. Characterization of topoisomerase Ⅱα gene amplification and deletion in breast cancer [J]. Genes Chromosomes Cancer, 1999, 26(2): 142-150.
[6]	Hicks DG, Yoder BJ, Pettay J，et al. The incidence of topoisomerase Ⅱ-α genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study [J]. Hum Pathol, 2005, 36(4): 348-356.
[7]	Jarvinen TA, Tanner M, Rantanen V，et al. Amplification and deletion of topoisomerase Ⅱα associate with ErbB-2 amplification and affect sensitivity to topoisomerase Ⅱ inhibitor doxorubicin in breast cancer [J]. Am J Pathol, 2000, 156(3): 839-847.
[8]	邹燕鹏，胡惠军，郝素贞，等. 拓扑异构酶Ⅱ和人类表皮生长因子受体在乳腺癌中的表达及意义 [J]. 河北医药，2018，40(17): 2619-2622.
[9]	Fountzilas G, Dafni U, Bobos M，et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase Ⅱ α gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase Ⅲ trials [J]. BMC Cancer, 2013, 13: 163.
[10]	O’Malley FP, Chia S, Tu D，et al. Topoisomerase Ⅱα protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial [J]. Breast Cancer Res Treat, 2011, 128(2): 401-409.
[11]	Brase JC, Schmidt M, Fischbach T，et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction [J]. Clin Cancer Res, 2010, 16(8): 2391-2401.
[12]	Romero A, Martin M, Cheang MC，et al. Assessment of topoisomerase Ⅱα status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization [J]. Am J Pathol, 2011, 178(4): 1453-1460.
[13]	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100，000 women in 123 randomised trials [J]. Lancet, 2012, 379(9814): 432-444.
[14]	Beretta GL, Zunino F. Molecular mechanisms of anthracycline activity [J]. Top Curr Chem, 2008, 283: 1-19.
[15]	Nikolenyi A, Uhercsak G, Csenki M，et al. Tumour topoisomerase Ⅱα protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy [J]. Pathol Oncol Res, 2012, 18(1): 61-68.
[16]	Schindlbeck C, Mayr D, Olivier C，et al. Topoisomerase Ⅱα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer [J]. J Cancer Res Clin Oncol, 2010, 136(7): 1029-1037.
[17]	Manna Edel F, Teixeira LC, Alvarenga M. Association between immunohistochemical expression of topoisomerase Ⅱα，HER2 and hormone receptors and response to primary chemotherapy in breast cancer [J]. Tumori, 2006, 92(3): 222-229.
[18]	Biesaga B, Niemiec J, Ziobro M，et al. Prognostic potential of topoisomerase Ⅱα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy [J]. Breast, 2011, 20(4): 338-350.
[19]	Mukherjee A, Shehata M, Moseley P，et al. Top2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer [J]. Br J Cancer, 2010, 103(12): 1794-1800.
[20]	Nikolenyi A, Sukosd F, Kaizer L，et al. Tumor topoisomerase Ⅱ α status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer [J]. Oncology, 2011, 80(3-4): 269-277.
[21]	El Rebey HS, Aiad HA, Abulkheir IL，et al. The predictive and prognostic role of topoisomerase Ⅱα and tissue inhibitor of metalloproteinases 1 expression in locally advanced breast carcinoma of Egyptian patients treated with anthracycline-based neoadjuvant chemotherapy [J]. Appl Immunohistochem Mol Morphol, 2016, 24(3): 167-178.
[22]	Rao N, Qiu J, Wu J，et al. Significance of tumor-infiltrating lymphocytes and the expression of topoisomerase Ⅱα in the prediction of the clinical outcome of patients with triple-negative breast cancer after taxane-anthracycline-based neoadjuvant chemotherapy [J]. Chemotherapy, 2017, 62(4): 246-255.
[23]	Chen S, Huang L, Liu Y，et al. The predictive and prognostic significance of pre- and post-treatment topoisomerase Ⅱα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer [J]. Eur J Surg Oncol, 2013, 39(6): 619-626.
[24]	Tinari N, Lattanzio R, Natoli C，et al. Changes of topoisomerase Ⅱα expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival [J]. Clin Cancer Res, 2006, 12(5): 1501-1506.
[25]	Yu Y, Xiang H, He XM，et al. Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience [J]. Asian Pac J Cancer Prev, 2013, 14(4): 2401-2406.
[26]	Wachter DL, Fasching PA, Haeberle L，et al. Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients [J]. Arch Gynecol Obstet, 2013, 287(2): 337-344.
[27]	Moretti E, Desmedt C, Biagioni C，et al. TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer [J]. Future Oncol, 2013, 9(10): 1477-1487.
[28]	Gomez HL, Pinto JA, Olivera M，et al. Topoisomerase Ⅱ-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer [J]. Breast, 2011, 20(1): 39-45.
[29]	Konecny GE, Pauletti G, Untch M，et al. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer [J]. Breast Cancer Res Treat, 2010, 120(2): 481-489.
[30]	Norimura S, Kontani K, Kubo T，et al. Candidate biomarkers predictive of anthracycline and taxane efficacy against breast cancer [J]. J Cancer Res Ther, 2018, 14(2): 409-415.
[31]	Durbecq V, Paesmans M, Cardoso F，et al. Topoisomerase-Ⅱα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel [J]. Mol Cancer Ther, 2004, 3(10): 1207-1214.
[32]	Cardoso F, Durbecq V, Larsimont D，et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase Ⅱ-α gene amplification and protein overexpression in locally advanced/metastatic breast cancer [J]. Int J Oncol, 2004, 24(1): 201-209.
[33]	Jarvinen TA, Holli K, Kuukasjarvi T，et al. Predictive value of topoisomerase Ⅱ α and other prognostic factors for epirubicin chemotherapy in advanced breast cancer [J]. Br J Cancer, 1998, 77(12): 2267-2273.
[34]	Lynch BJ, Guinee DG Jr, Holden JA. Human DNA topoisomerase Ⅱ-α：a new marker of cell proliferation in invasive breast cancer [J]. Hum Pathol, 1997, 28(10): 1180-1188.
[35]	Depowski PL, Rosenthal SI, Brien TP，et al. Topoisomerase Ⅱα expression in breast cancer: correlation with outcome variables [J]. Mod Pathol, 2000, 13(5): 542-547.
[36]	Fritz P, Cabrera CM, Dippon J，et al. c-erbB2 and topoisomerase Ⅱα protein expression independently predict poor survival in primary human breast cancer: a retrospective study [J]. Breast Cancer Res, 2005, 7(3): R374-384.
[37]	An X, Xu F, Luo R，et al. The prognostic significance of topoisomerase Ⅱα protein in early stage luminal breast cancer [J]. BMC Cancer, 2018, 18(1): 331.
[38]	Qiao JH, Jiao DC, Lu ZD，et al. Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer [J]. Tumour Biol, 2015, 36(9): 6833-6838.
[39]	Jacot W, Fiche M, Zaman K，et al. The HER2 amplicon in breast cancer: Topoisomerase ⅡA and beyond [J]. Biochim Biophys Acta, 2013, 1836(1): 146-157.
[40]	Fountzilas G, Valavanis C, Kotoula V，et al. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy [J]. J Transl Med, 2012, 10: 10.
[41]	Susini T, Berti B, Carriero C，et al. Topoisomerase Ⅱα and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer [J]. Onco Targets Ther, 2014, 7: 2111-2120.

Please choose a citation manager

Content to export